{"classes":[{"categories":[{"measurements":[{"comment":"Below the level of detection.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.1","value":"80.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"}],"units":"Participants"}],"title":"Cycle 3 Day1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.4","value":"138"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.5","value":"186"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.1","value":"196"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.4","value":"221"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 24 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"}],"units":"Participants"}],"description":"Atezolizumab pre-dose plasma concentration (Cmin) for each respective day.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"MEAN","populationDescription":"PK analyses were based on PK observations from all participants who had received atezolizumab, carboplatin, or etoposide treatment and who provided at least one evaluable atezolizumab PK sample.","reportingStatus":"POSTED","timeFrame":"Predose on Day 1 of Cycles 1, 3, 4, 8, 16 and 24 (cycle length = 21 days)","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab in the Global Population","type":"SECONDARY","unitOfMeasure":"μg/mL"}